Intraocular implants for extended drug delivery: Therapeutic applications

Bourges, Jean‐Louis; Bloquel, Carole; Thomas, Aurélien; Froussart, F.; Bochot, Amélie; Azan, F.; Gurny, Robert; BenEzra, David; Behar‐Cohen, Francine

doi:10.1016/j.addr.2006.07.026

Cited by 212 publications

(150 citation statements)

References 115 publications

Supporting

Mentioning

140

Contrasting

Unclassified

Order By: Relevance

“…PCL degrades through hydrolysis due to ester bonds. However, the degradation rate of PCL is slow (2 to 3 years) (Bourges et al, 2006;Nair, Laurencin, 2007). The slow degradation, high biocompatibility, and high permeability of drugs are characteristics of PCL that have been investigated to develop controlled drug delivery devices in the eye (Kimura, Ogura, 2001;Dong et al, 2006;Peyman, Ganiban, 2006;Fialho et al, 2008).…”

Section: Biodegradable Implantsmentioning

confidence: 99%

“…Several studies have been carried out in an attempt to develop non-biodegradable intraocular implants containing ganciclovir for the treatment of cytomegalovirus retinitis Martin et al, 1994Sanborn et al, 1992Charles, Steiner, 1996). These studies were performed on animals and humans and, in 1996, led to the development of Vitrasert ® (Bausch & Lomb, USA) and its approval by the Food and Drug Administration (FDA) (Bourges et al, 2006). Vitrasert ® is a controlled-release intraocular implant that contains 4.5mg of ganciclovir.…”

Section: Non-biodegradable Implants In the Treatment Of Cytomegalovirmentioning

confidence: 99%

“…The viscous nature of this polymer allows the incorporation of therapeutic substances without the use of organic solvents. Moreover, POE III can be injected directly into the eye using appropriate needles (Bourges et al, 2006;Nair, Laurencin, 2007). The intracameral and intravitreal biocompatibility of POE II has been extensively investigated.…”

Section: Biodegradable Implantsmentioning

confidence: 99%

“…The release kinetics of the drug from this system suggest that if the concentration of the drug within the reservoir is in constant equilibrium with the inner surface of the enclosed membrane, the driving force for diffusional release of the agent is constant, and zero order release kinetics of the drug from the delivery system is achieved. The drug-release rate is determined by different factors, such as the release area, the thickness of the polymeric membrane, the implant form, as well as drug solubility (Bourges et al, 2006).…”

Section: Non-biodegradable Implantsmentioning

confidence: 99%

“…Polymers, such as silicon and PVA, are easily permeable for a variety of lipophilic drugs due to their hydrophobic characteristics. EVA is impermeable to most drugs and is used as a membrane around the reservoir to reduce the rate of drug diffusion through the implant Dash, Cudworth, 1998;Yasukawa et al, 2004;Bourges et al, 2006).…”

Section: Non-biodegradable Implantsmentioning

confidence: 99%

See 4 more Smart Citations

Implants as drug delivery devices for the treatment of eye diseases

Silva

Fialho

Siqueira³

et al. 2010

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

The treatment of diseases affecting the posterior segment of the eye is limited by the difficulty in transporting effective doses of drugs to the vitreous, retina, and choroid. Topically applied drugs are poorly absorbed due to the low permeability of the external ocular tissues and tearing. The blood-retina barrier limits drug diffusion from the systemic blood to the posterior segment, thus high doses of drug are needed to maintain therapeutic levels. In addition, systemic side effects are common. Intraocular injections could be an alternative, but the fast flowing blood supply in this region, associated with rapid clearance rates, causes drug concentration to quickly fall below therapeutic levels. To obtain therapeutic levels over longer time periods, polymeric sustained-drug release systems implanted within the vitreous are being studied for the treatment of vitreoretinal disorders. These systems are prepared using different kinds of biodegradable or non-biodegradable polymers. This review aims to demonstrate the main characteristics of these drug delivery implants and their potential for clinical application.Uniterms: Implants/biodegradation. Drugs/delivery systems. Drugs/prolonged delivery systems. Pharmaceutical technology.O tratamento de doenças do segmento posterior do olho é limitado pela dificuldade no transporte de doses efetivas de fármacos para o vítreo, retina e coróide. Os fármacos aplicados topicamente são pouco absorvidos por causa da baixa permeabilidade dos tecidos oculares externos e ao lacrimejamento. Embora a administração sistêmica seja capaz de transportar fármacos para o segmento posterior do olho, as barreiras hemato-aquosa e hematorretiniana dificultam a absorção e, normalmente, são necessárias doses elevadas, as quais estão geralmente associadas a potenciais efeitos adversos. Injeções intravitreais são capazes de transportar fármacos para o segmento posterior do olho, mas é uma técnica invasiva, pouco tolerada pelos pacientes e apresenta riscos de infecções oculares e danos aos tecidos. Visando a obtenção de níveis terapêuticos adequados de fármacos no segmento posterior do bulbo do olho por longos períodos, sistemas de liberação poliméricos implantados diretamente no vítreo estão sendo investigados para o tratamento de várias doenças vítreo-retinianas. Esses implantes podem ser preparados a partir de diferentes polímeros biocompatíveis, biodegradáveis ou não-biodegradáveis. Nesta revisão, as principais características destes implantes transportadores de fármacos são descritas, expondo suas potencialidades de aplicação clínica.Unitermos: Implantes oculares/biodegradação. Fármacos/sistemas de liberação. Fármacos/ Fármacos/ ação prolongada. Tecnologia farmacêutica.

show abstract

Section: Biodegradable Implantsmentioning

confidence: 99%

Section: Non-biodegradable Implants In the Treatment Of Cytomegalovirmentioning

confidence: 99%

Section: Biodegradable Implantsmentioning

confidence: 99%

Section: Non-biodegradable Implantsmentioning

confidence: 99%

Section: Non-biodegradable Implantsmentioning

confidence: 99%

See 3 more Smart Citations

Implants as drug delivery devices for the treatment of eye diseases

Silva

Fialho

Siqueira³

et al. 2010

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

Polymeric Materials in Ocular Drug Delivery Systems

Pina

Coimbra

Ferreira

et al. 2015

Handbook of Polymers for Pharmaceutical Technologies

View full text Add to dashboard Cite

MEMS: Enabled Drug Delivery Systems

Cobo

Sheybani

Meng

2015

Adv Healthcare Materials

View full text Add to dashboard Cite

Drug delivery systems play a crucial role in the treatment and management of medical conditions. Microelectromechanical systems (MEMS) technologies have allowed the development of advanced miniaturized devices for medical and biological applications. This Review presents the use of MEMS technologies to produce drug delivery devices detailing the delivery mechanisms, device formats employed, and various biomedical applications. The integration of dosing control systems, examples of commercially available microtechnology-enabled drug delivery devices, remaining challenges, and future outlook are also discussed.

show abstract

Intraocular implants for extended drug delivery: Therapeutic applications

Cited by 212 publications

References 115 publications

Implants as drug delivery devices for the treatment of eye diseases

Implants as drug delivery devices for the treatment of eye diseases

Polymeric Materials in Ocular Drug Delivery Systems

MEMS: Enabled Drug Delivery Systems

Contact Info

Product

Resources

About